Patents by Inventor Jiaxin Yu

Jiaxin Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10975064
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to inhibit a RIP1 kinase in vivo or ex vivo, and also may treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: April 13, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
  • Publication number: 20210078990
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: November 25, 2020
    Publication date: March 18, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
  • Patent number: 10947196
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: March 16, 2021
    Assignee: CuraSen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20210069208
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Inventors: Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
  • Publication number: 20210070743
    Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 11, 2021
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
  • Patent number: 10889562
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: January 12, 2021
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Patent number: 10851093
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, X, Y1, Y2, Y3 and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: December 1, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
  • Publication number: 20200369644
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Patent number: 10822337
    Abstract: Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, X, Z, m, p, and R2 are as described herein. In certain embodiments, a compound disclosed herein inhibits the activity of one or more members of the TGF-? superfamily, and can be used to treat disease by blocking such activity.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: November 3, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
  • Publication number: 20200308115
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20200308114
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20200299276
    Abstract: Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and heteroaryl; and R2 and R3 are independently selected from hydrogen and (C1-C6)alkyl. Disclosed compounds may have an IRAK4 IC50 of from 0.003 ?M to 3.7 M; a TAK1 IC50 of from 0.008 ?M to 132 M; and/or an IRAK4/TAK1 selectivity of from 1 to 450. Particular compounds may have an IRAK4/TAK1 selectivity of from 100 to 500. Disclosed compositions may be formulated as pharmaceutical compositions. A method for using the compounds and/or compositions also are disclosed. The method may comprise administering to a subject an effective amount of a compound within the scope of the present invention, particularly to selectively inhibit IRAK 1 and/or IRAK4 over TAK1.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
  • Patent number: 10774066
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Patent number: 10710983
    Abstract: Compounds within the scope of the present invention have a Formula 1 or a salt or prodrug thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and heteroaryl; and R2 and R3 are independently selected from hydrogen and (C1-C6)alkyl. Disclosed compounds may have an IRAK4 IC50 of from 0.003 ?M to 3.7 ?M; a TAK1 IC50 of from 0.008 ?M to 132 ?M; and/or an IRAK4/TAK1 selectivity of from 1 to 450. Particular compounds may have an IRAK4/TAK1 selectivity of from 100 to 500. Disclosed compositions may be formulated as pharmaceutical compositions. A method for using the compounds and/or compositions also are disclosed. The method may comprise administering to a subject an effective amount of a compound within the scope of the present invention, particularly to selectively inhibit IRAK 1 and/or IRAK4 over TAK1.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 14, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
  • Patent number: 10696693
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure Formula (I) and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein A, Z, X, R1, R2 m, p and a are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-?, and can be used to treat disease by blocking TGF-? signaling.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 30, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Todd Kinsella, Jiaxin Yu, Marina Gelman, Ihab S. Darwish
  • Publication number: 20200155531
    Abstract: Aspects of the present disclosure include compounds that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 14, 2019
    Publication date: May 21, 2020
    Inventors: Matthew Duncton, Somasekhar Bhamidipati, Jiaxin Yu, Ihab Darwish, Rajinder Singh
  • Publication number: 20200111212
    Abstract: A chromosome abnormality detecting system includes an image capturing unit and a non-transitory machine readable medium. The image capturing unit is for obtaining a target metaphase chromosomes image of a subject. The non-transitory machine readable medium storing a program which, when executed by at least one processing unit, determines whether the subject has a chromosome abnormality when executed by a processing unit. The program includes a reference database obtaining module, a reference image transforming module, a reference preliminary classifying module, a reference feature selecting module, a training module, a target image transforming module, a target preliminary classifying module, a target feature selecting module and a comparing module.
    Type: Application
    Filed: July 18, 2019
    Publication date: April 9, 2020
    Inventors: Fuu-Jen Tsai, Tzung-Chi Huang, Ken Ying-Kai Liao, Jiaxin Yu, Po-Hsin Hsieh
  • Publication number: 20200078348
    Abstract: Disclosed are imidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, Y and Z are as described herein. In certain embodiments, a compound disclosed herein inhibits a cellular TAM receptor, and can be used to treat disease mediated by or involving the TAM receptor family.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 12, 2020
    Inventors: Sacha Holland, Rajinder Singh, Somasekhar Bhamidipati, Pingyu Ding, Rao Kolluri, Ihab Darwish, Esteban Masuda, Jiaxin Yu
  • Patent number: 10565911
    Abstract: A device for detection of a display panel is provided in the embodiments of the disclosure, which is configured to detect signal lines on the display panel. The signal lines at least comprises a plurality of data lines which are divided into N groups; the device comprises: N shorting bars provided within an electrode lead region of the display panel to intersect the plurality of data lines, a plurality of welding pads provided on both sides of the electrode lead region, each of which shorting bars short-circuits one of the N groups of data lines together and connects with two welding pad at both ends thereof respectively, and a switch which is provided between each of the shorting bars and each of the corresponding welding pads connecting with the former on one and the same side of all the shorting bars; and N is a positive integer not less than.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 18, 2020
    Assignees: BOE TECHNOLOGY GROUP CO., LTD., BEIJING BOE DISPLAY TECHNOLOGY CO., LTD
    Inventors: Wei Li, Minghui Ma, Jinhu Cao, Bin Cao, Kwon Namin, Jiaxin Yu, Fengwu Yu, Mian Gao
  • Patent number: 10558101
    Abstract: An array substrate motherboard includes a substrate including a plurality of gate lines, a plurality of gate line driving leads, a plurality of data lines, and a plurality of data line driving leads; a plurality of gate line testing leads; a plurality of data line testing leads and a plurality of data line driving leads; a plurality of gate line testing pads; a plurality of data line testing pads; and an insulating layer arranged between the data line testing leads and the data line driving leads in the trimming region. A respective one of the plurality of data line testing pads is connected with a respective one of the plurality of data line testing leads. A respective one of the plurality of data line driving leads is connected with one of the plurality of data line testing leads that penetrate through the insulating layer.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: February 11, 2020
    Assignees: BOE Technology Group Co., Ltd., BEIJING BOE DISPLAY TECHNOLOGY CO., LTD.
    Inventors: Jinhu Cao, Minghui Ma, Jiaxin Yu, Fengwu Yu, Bin Cao, Namin Kwon, Wei Li, Zhi Li, Xinlei Cao, Enke Guo